The 13 analysts offering 1 year price forecasts for PACB have a max estimate of — and a min estimate of —.
Analyst rating
Based on 16 analysts giving stock ratings to PACB in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
Be warned
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
PACB EPS for the last quarter is −0.22 USD despite the estimation of −0.22 USD. In the next quarter EPS is expected to reach −0.21 USD. Track more of Pacific Biosciences of California, Inc. financials and stay on top of what is up with the company.
We've gathered opinions of 16 analysts rating PACB stock in the past 3 months. Most of them backed up the neutral trend, and after taking into account other opinions, the overall rating was calculated as buy. Note that it's not a trading advice — your own analysis is still required.